Increased Galectin-1 Expression in Thymic Epithelial Tumors

Jonathan Riess; Christina S. Kong; Robert B. West; Sukhmani K. Padda; Joel W. Neal; Heather A. Wakelee; Quynh Thu Le

doi:10.1016/j.cllc.2018.12.005

Increased Galectin-1 Expression in Thymic Epithelial Tumors

Jonathan Riess, Christina S. Kong, Robert B. West, Sukhmani K. Padda, Joel W. Neal, Heather A. Wakelee, Quynh Thu Le

Hematology and Oncology

Research output: Contribution to journal › Article

1 Scopus citations

Abstract

Thymic malignancies are rare tumors where lack of preclinical models adversely affect development of new therapies. Galectin-1 is an important protein in cancer involved in maintaining an immunosuppressive environment. This study examined galectin-1 expression in a large thymic epithelial tumor issue microarray and found elevated expression compared to benign thymus controls. Galectin-1 is a potential therapeutic target in thymic malignancies.

Original language	English (US)
Journal	Clinical Lung Cancer
DOIs	https://doi.org/10.1016/j.cllc.2018.12.005
State	Published - Jan 1 2019

Keywords

Thymic malignancy
Tumor microenvironment

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.cllc.2018.12.005

Fingerprint Dive into the research topics of 'Increased Galectin-1 Expression in Thymic Epithelial Tumors'. Together they form a unique fingerprint.

Cite this

Riess, J., Kong, C. S., West, R. B., Padda, S. K., Neal, J. W., Wakelee, H. A., & Le, Q. T. (2019). Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2018.12.005

@article{910979b53512497a91e808c4e8c03e6b,

title = "Increased Galectin-1 Expression in Thymic Epithelial Tumors",

abstract = "Thymic malignancies are rare tumors where lack of preclinical models adversely affect development of new therapies. Galectin-1 is an important protein in cancer involved in maintaining an immunosuppressive environment. This study examined galectin-1 expression in a large thymic epithelial tumor issue microarray and found elevated expression compared to benign thymus controls. Galectin-1 is a potential therapeutic target in thymic malignancies.",

keywords = "Thymic malignancy, Tumor microenvironment",

author = "Jonathan Riess and Kong, {Christina S.} and West, {Robert B.} and Padda, {Sukhmani K.} and Neal, {Joel W.} and Wakelee, {Heather A.} and Le, {Quynh Thu}",

year = "2019",

month = jan,

day = "1",

doi = "10.1016/j.cllc.2018.12.005",

language = "English (US)",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

}

TY - JOUR

T1 - Increased Galectin-1 Expression in Thymic Epithelial Tumors

AU - Riess, Jonathan

AU - Kong, Christina S.

AU - West, Robert B.

AU - Padda, Sukhmani K.

AU - Neal, Joel W.

AU - Wakelee, Heather A.

AU - Le, Quynh Thu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Thymic malignancies are rare tumors where lack of preclinical models adversely affect development of new therapies. Galectin-1 is an important protein in cancer involved in maintaining an immunosuppressive environment. This study examined galectin-1 expression in a large thymic epithelial tumor issue microarray and found elevated expression compared to benign thymus controls. Galectin-1 is a potential therapeutic target in thymic malignancies.

AB - Thymic malignancies are rare tumors where lack of preclinical models adversely affect development of new therapies. Galectin-1 is an important protein in cancer involved in maintaining an immunosuppressive environment. This study examined galectin-1 expression in a large thymic epithelial tumor issue microarray and found elevated expression compared to benign thymus controls. Galectin-1 is a potential therapeutic target in thymic malignancies.

KW - Thymic malignancy

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85061433479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061433479&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2018.12.005

DO - 10.1016/j.cllc.2018.12.005

M3 - Article

C2 - 30773448

AN - SCOPUS:85061433479

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -